Unique ID issued by UMIN | UMIN000041507 |
---|---|
Receipt number | R000047355 |
Scientific Title | Database study of adverse events in atezolizumab combination with carboplatin plus paclitaxel with bevacizumab therapy in patients with previously untreated unresectable advanced or recurrent non-squamous non-small cell lung cancer |
Date of disclosure of the study information | 2020/08/21 |
Last modified on | 2020/08/20 16:05:54 |
Database study of adverse events in atezolizumab combination with carboplatin plus paclitaxel with bevacizumab therapy in patients with previously untreated unresectable advanced or recurrent non-squamous non-small cell lung cancer
Database study of adverse events in atezolizumab combination with carboplatin plus paclitaxel with bevacizumab therapy in patients with previously untreated unresectable advanced or recurrent non-squamous non-small cell lung cancer
Database study of adverse events in atezolizumab combination with carboplatin plus paclitaxel with bevacizumab therapy in patients with previously untreated unresectable advanced or recurrent non-squamous non-small cell lung cancer
Database study of adverse events in atezolizumab combination with carboplatin plus paclitaxel with bevacizumab therapy in patients with previously untreated unresectable advanced or recurrent non-squamous non-small cell lung cancer
Japan |
Non-small cell lung cancer
Pneumology | Hematology and clinical oncology |
Malignancy
NO
To investigate the safety of atezolizumab combination with carboplatin plus paclitaxel with bevacizumab therapy using a database from DPC in patients with previously untreated unresectable advanced or recurrent non-squamous non-small cell lung cancer in Japan
Safety
Incidence, rates, severity and time to onset of adverse events, and treatment for adverse events
Observational
Not applicable |
Not applicable |
Male and Female
Patients with non-squamous non-small cell lung cancer
Patients who have been diagnosed with malignant tumors other than non-squamous non-small cell lung cancer and have undergone chemotherapy for non-small cell lung cancer
400
1st name | Kaori |
Middle name | |
Last name | Ouchi |
CHUGAI PHARMACEUTICAL CO., LTD.
Medical Affairs Div.
103-8324
1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo 103-8324, Japan
0332730866
cma-clinicaltrial@chugai-pharm.co.jp
1st name | CHUGAI PHARMACEUTICAL |
Middle name | |
Last name | CO., LTD. |
Medical Affairs Div.
Medical Science Dept.
103-8324
1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo 103-8324, Japan
0332730866
cma-clinicaltrial@chugai-pharm.co.jp
CHUGAI PHARMACEUTICAL CO., LTD.
CHUGAI PHARMACEUTICAL CO., LTD.
Profit organization
Japan
Non-Profit Organization MINS Institutional Review Board
1-15-14, Dogenzaka, Shibuya, Tokyo, Japan
0364161868
npo-mins@j-irb.com
NO
2020 | Year | 08 | Month | 21 | Day |
Unpublished
Preinitiation
2020 | Year | 06 | Month | 18 | Day |
2020 | Year | 06 | Month | 18 | Day |
2020 | Year | 08 | Month | 24 | Day |
2020 | Year | 12 | Month | 31 | Day |
A cohort study using a Japanese healthcare database
2020 | Year | 08 | Month | 21 | Day |
2020 | Year | 08 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047355
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |